In patients with high serum AFP levels, patients with high serum myostatin levels had a significantly higher HCC risk than those with low serum myostatin levels (HR 5.22, 95% CI 2.77–9.86, p < 0.001). The gene discussed is MSTN; the disease is hepatocellular carcinoma.